IBA signs contract with IAEA for the installation of a Cyclone® KEY in Benin, West Africa
February 29 2024 - 1:00AM
IBA signs contract with IAEA for the installation of a
Cyclone® KEY in Benin, West Africa
Contract with IAEA
demonstrates Cyclone® KEY’s accessibility for low- and
middle-income countries
Louvain-la-Neuve, Belgium, February 29,
2024 – IBA (Ion Beam Applications S.A.,
EURONEXT), the world leader in particle accelerator technology and
the world’s leading provider of radiopharmaceutical production
solutions, is pleased to announce that it has signed a contract for
a Cyclone® KEY cyclotron with the International Atomic Energy
Agency (IAEA). This cyclotron will be installed at the University
Hospital of Reference (Centre Hospitalier et Universitaire de
Référence), in Cotonou Benin in West Africa. It marks the first
sale of this compact version of IBA’s Cyclone®.
Today’s contract follows IBA winning an IAEA
tender to be one of the projects included in the “Rays of Hope”
initiative, which provides radiation support, whether in
infrastructure, safety legislation, quality control, guidance,
training or essential equipment to countries without radiotherapy
or equitable access. Rays of Hope focuses on prioritizing a limited
number of high-impact, cost-effective and sustainable interventions
in line with national needs and commitment.
The typical price for a Cyclone® KEY ranges from
EUR 1.9 million to EUR 3.2 million, depending on the configuration
and options. The contract was signed at the end of December 2023
and IBA has received the first payment.
Bruno Scutnaire, President at IBA
RadioPharma Solutions, added: “We are proud to have been
chosen by the IAEA to be one of its Ray of Hope projects. Positron
Emission Tomography (PET) imaging is well-established for cancer
diagnosis in many countries, however, there are still regions in
the world with limited access to this technology. This contract
demonstrates how IBA’s Cyclone® KEY has the potential to make PET
imaging more accessible globally.”
The Cyclone® KEY was launched to enable small
and medium-sized hospitals to produce their own radiopharmaceutical
products in-house, whilst providing widespread global access to
diagnostic solutions in oncology, neurology, and cardiology,
especially to regions in the world with limited access to this
diagnostic technology. IBA is making PET imaging more accessible
through this low-energy technology, comprising proton acceleration
up to 9.2 megaelectron volts (MeV).
***ENDS***
About IBA
IBA (Ion Beam Applications S.A.) is the world
leader in particle accelerator technology. The company is the
leading supplier of equipment and services in the field of proton
therapy, considered to be the most advanced form of radiation
therapy available today. IBA is also a leading player in the fields
of industrial sterilization, radiopharmaceuticals and dosimetry.
The company, based in Louvain-la-Neuve, Belgium, employs
approximately 2,000 people worldwide. IBA is a certified B
Corporation (B Corp) meeting the highest standards of verified
social and environmental performance.
IBA is listed on the pan-European stock exchange
EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).
More information can be found at:
www.iba-worldwide.com
CONTACTS
Soumya ChandramouliChief
Financial Officer+32 10 475 890Investorrelations@iba-group.com
Olivier LechienCorporate
Communication Director+32 10 475 890communication@iba-group.com
ICR Consilium Amber Fennell,
Lucy Featherstone+44 (0) 20 3709 5700IBA@consilium-comms.com
- 240229-IBA-IAEA-Benin-KEY-EN
Ion Beam Applications (EU:IBAB)
Historical Stock Chart
From Oct 2024 to Nov 2024
Ion Beam Applications (EU:IBAB)
Historical Stock Chart
From Nov 2023 to Nov 2024
